Andrea Schmidts MD

Dr. Andrea Schmidts studied medicine in Freiburg and Aberdeen. In 2013, she started her clinical training in internal medicine with a focus on hematology, oncology, and stem cell transplantation at the University Medical Center Freiburg. From 2017-2022, she worked on adoptive cell therapies for cancer treatment in Prof. Marcela Maus's lab at Massachusetts General Hospital and Harvard Medical School. In 2022, she moved to the Technical University of Munich to start her own Emmy Noether research group at TranslaTUM and the Department of Medicine III.

Dr. Schmidts develops engineered T cell therapies for cancer treatment. The focus of her laboratory is to understand and combat cancer cell resistance to CAR-T cell therapy. Dr. Schmidts has established a high-throughput CRISPR platform that allows for the functional characterization of tumor antigen variants, and she uses the newest gene editing technologies to engineer CAR-T cells with improved resilience. Ultimately, she aims to translate resilient CAR-T cell therapies into early-phase clinical trials for cancer patients.